SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT03647592

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Real World Study to Evaluate the Efficacy and Resistant Mechanism of Erlotinib/Gefitinib Combined With Bevacizumab in First Line EGFR Mutation Positive Advanced Non-aquamous Non-small Cell Lung Cancer

This study aims to explore the efficacy and safety of Erlotinib/Gefitinib combined with bevacizumab in the real world for advanced non-squamous cell lung cancer with EGFR mutation, explore new drug resistance mechanisms under the A+T regimen and consistency between plasma and tissue detection driving genes, and finally assess the predictive value of plasma dynamic detection driving gene mutation profiles in predicting disease. The role of disease progression risk.

NCT03647592 Efficacy and Safety of Erlotinib/Gefitinib Combined With Bevacizumab in EGFR Mutation Positive Advanced Non-squamous Non-small Cell Lung Cancer
MeSH: Lung Neoplasms Carcinoma, Non-Small-Cell Lung
HPO: Neoplasm of the lung Non-small cell lung carcinoma

1 Interventions

Name: Erlotinib/Gefitinib combined with Bevacizumab

Description: Erlotlnib,150mg po qd/gefitinib 250mg po qd +Bevacizumab(15mg/kg),lvgtt,every 21 day ,evaluate every 2 months

Type: Drug

Cohorts 1


Primary Outcomes

Description: Progression free survival

Measure: PFS

Time: Approximately 1 years

Secondary Outcomes

Description: Overall survival

Measure: OS

Time: Approximately 1 years

Description: Disease control rate

Measure: DCR

Time: Approximately 1 years

Time Perspective: Retrospective

Cohort


There is one SNP

SNPs


1 L858R

Inclusion Criteria: - EGFR mutation(19del/L858R) - advanced non-saquamous non-small cell lung cancer - primary treatment of first diagnosis - performance status(0-1) Exclusion Criteria: - other genes mutation - saquamous Inclusion Criteria: - EGFR mutation(19del/L858R) - advanced non-saquamous non-small cell lung cancer - primary treatment of first diagnosis - performance status(0-1) Exclusion Criteria: - other genes mutation - saquamous Efficacy and Safety of Erlotinib/Gefitinib Combined With Bevacizumab in EGFR Mutation Positive Advanced Non-squamous Non-small Cell Lung Cancer Lung Neoplasms Carcinoma, Non-Small-Cell Lung A retrospective study of 30 cases of advanced non-squamous non-small cell lung cancer (NSCLC) with EGFR mutation positive treated with A+T was conducted to observe the efficacy and safety of A+T regimen in the real world. --- L858R ---

Inclusion Criteria: - EGFR mutation(19del/L858R) - advanced non-saquamous non-small cell lung cancer - primary treatment of first diagnosis - performance status(0-1) Exclusion Criteria: - other genes mutation - saquamous Inclusion Criteria: - EGFR mutation(19del/L858R) - advanced non-saquamous non-small cell lung cancer - primary treatment of first diagnosis - performance status(0-1) Exclusion Criteria: - other genes mutation - saquamous Efficacy and Safety of Erlotinib/Gefitinib Combined With Bevacizumab in EGFR Mutation Positive Advanced Non-squamous Non-small Cell Lung Cancer Lung Neoplasms Carcinoma, Non-Small-Cell Lung A retrospective study of 30 cases of advanced non-squamous non-small cell lung cancer (NSCLC) with EGFR mutation positive treated with A+T was conducted to observe the efficacy and safety of A+T regimen in the real world. --- L858R --- --- L858R ---



HPO Nodes


HPO:
Neoplasm of the lung
Genes 43
WT1 KRAS SLC22A18 STK11 IRF1 AKT1 C11ORF95 PRKN PPP2R1B ERBB2 TRPV3 TSC1 POU6F2 TSC2 EWSR1 RELA KEAP1 REST DIS3L2 SFTPA2 GPC3 MBTPS2 LMNA PTEN BRAF BRCA2 EGFR RB1 TRIP13 PDGFRB TERT SFTPC PIK3CA TRIM28 DICER1 MAP3K8 HPGD SLCO2A1 H19 TP53 NOTCH3 BAP1 WRN
Non-small cell lung carcinoma
Genes 2
TP53 BAP1